News | January 25, 2012

Terumo Becomes Exclusive U.S. Distributor for TigerPaw II Left Atrial Appendage Occluder

January 25, 2012 — Terumo Cardiovascular Systems entered into an exclusive agreement with LAAx Inc. to distribute the TigerPaw System II, a left atrial appendage (LAA) closure device in the United States.

The TigerPaw System II is indicated for occlusion of the left atrial appendage under direct visualization, in conjunction with other open cardiac procedures. It is new to the market following successful completion of a clinical trial. During its clinical trial, the TigerPaw System II provided 100 percent occlusion at both post-op and at 90 days.

"Terumo's broad distribution network will be a tremendous asset," said Bill Wheeler, president and CEO of LAAx. "We will work together to get the TigerPaw System II into the hands of cardiac surgeons who have not yet had access to a clinically proven, 100 percent occlusive left atrial appendage (LAA) closure device … Risk mitigation is an important consideration for every cardiac surgeon who considers 100 percent occlusion to be the only acceptable medical outcome for LAA occlusion technologies."

For more information:

Related Content

Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery | May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery | February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery | November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
Overlay Init